A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...

Use of GIP and GLP-1 receptor agonists in prostate cancer patients. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Advances in next-generation sequencing (NGS) and synthetic DNA technologies are reshaping oncology research by enabling earlier cancer detection, more accurate biomarker discovery, and sensitive ...

IRVING, Texas, Aug. 13, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in ...

Attitudes and knowledge towards breast cancer among non-healthcare workers at an educational institution. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This abstract does ...

The global DNA methylation market size was valued at US$ 1.9 Bn in 2025 and is projected to reach US$ 7.7 Bn by 2036, growing ...

Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...